2019 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 46 pages | ID: 2E200F1ABF5EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Familial Chylomicronemia (Type I Hyperlipoproteinemia). It presents in-depth analysis of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Familial Chylomicronemia (Type I Hyperlipoproteinemia).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Familial Chylomicronemia (Type I Hyperlipoproteinemia)

The research work is prepared through extensive and continuous research on Familial Chylomicronemia (Type I Hyperlipoproteinemia) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Familial Chylomicronemia (Type I Hyperlipoproteinemia) patients are identified
• The report includes panorama of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Region
  2.2.2 Average Enrollment of Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Familial Chylomicronemia (Type I Hyperlipoproteinemia) Treatment, 2019

3. REGION WISE FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIALS

3.1 Asia Pacific Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country
3.2 Europe Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country
3.3 North America Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country
3.4 Middle East and Africa Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country
3.5 South and Central America Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

4. FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIAL TRENDS

4.1 Start Year wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials
4.2 Phase wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials
4.3 Trial Status wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials
4.4 Trial Type wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials

5. FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Year
5.2 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Phase
5.3 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Status
5.4 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIALS

6.1 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Sponsor Type
6.2 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase
7.2 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase
7.3 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase
7.4 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Figure 7: North America – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Figure 9: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Phase
Figure 10: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Trial Status
Figure 11: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Type
Figure 12: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Sponsor Type
Figure 13: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Leading Sponsors
Figure 14: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Phase
Figure 15: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Trial Status
Figure 16: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Type
Figure 17: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Average Enrolment by Type of Sponsors
Figure 18: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Table 5: Europe – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Table 7: North America – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Phase
Table 15: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Trial Status
Table 16: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Type
Table 17: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Average Enrolment by Type of Sponsors
Table 18: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Enrolment by Leading Sponsors